In the current study, we identified a mutation in Reg1cp and presented genetic, clinical, in vivo and in vitro experimental evidences to demonstrate that Reg1cp promotes the development of T2D both by impairing islet β cell function and increasing insulin resistance. The gene discussed is REG1CP; the disease is Insulin resistance.